Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis

Phase 2

Completed

Conditions: Alcoholic Hepatitis

Interventions: Drug: Anakinra and Zinc
Drug: Prednisone
Drug: Placebos

First Posted Date: 2019-08-28

Last Posted Date: 2023-07-28

Lead Sponsor: Indiana University

Target Recruit Count: 147

Registration Number: NCT04072822

Locations: 🇺🇸
University of Louisville, Louisville, Kentucky, United States
🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 5 locations

Treg Modulation With CD28 and IL-6 Receptor Antagonists

Phase 1

Completed

Conditions: Living-Donor Kidney Transplant
Kidney Transplant Recipients

Interventions: Biological: lulizumab pegol
Biological: antithymocyte globulin (rabbit)
Drug: methylprednisolone
Biological: tocilizumab
Drug: Prednisone
Drug: everolimus
Biological: belatacept
Drug: mycophenolate mofetil
Drug: mycophenolic acid

First Posted Date: 2019-08-26

Last Posted Date: 2024-10-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT04066114

Locations: 🇺🇸
Cleveland Clinic Foundation: Transplantation, Cleveland, Ohio, United States
🇺🇸
University of California San Francisco School of Medicine: Transplantation, San Francisco, California, United States
🇺🇸
University of Alabama School of Medicine: Transplantation, Birmingham, Alabama, United States

and more 4 locations

A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

Phase 2

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: Bortezomib
Drug: Etoposide
Drug: Cyclophosphamide
Drug: Pharmorubicin
Drug: Prednisone

First Posted Date: 2019-08-20

Last Posted Date: 2019-08-20

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 54

Registration Number: NCT04061772

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer

Phase 3

Completed

Conditions: Metastatic Castration Resistant Prostate Cancer

Interventions: Drug: Abiraterone Acetate
Drug: Placebo
Drug: Prednisone

First Posted Date: 2019-08-14

Last Posted Date: 2019-08-14

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 268

Registration Number: NCT04056754

Locations: 🇨🇳
TongJi medical college of HuaZhong University of Science & Technology Affiliated TongJi Hospital, Wuhan, Hubei, China
🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

and more 13 locations

Weekly Steroids in Muscular Dystrophy

Phase 2

Completed

Conditions: Limb-girdle Muscular Dystrophy
Becker Muscular Dystrophy

Interventions: Drug: Prednisone

First Posted Date: 2019-08-13

Last Posted Date: 2023-09-21

Lead Sponsor: Northwestern University

Target Recruit Count: 20

Registration Number: NCT04054375

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

Phase 3

Recruiting

Conditions: Lymphoblastic Lymphoma, Childhood

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Daunorubicin
Drug: Dexamethasone
Drug: 6-Mercaptopurine
Drug: Methotrexate
Drug: Doxorubicin
Drug: PEG asparaginase
Drug: Ifosfamide
Drug: Vincristine
Drug: Prednisone
Drug: Prednisolone
Drug: Thioguanine
Drug: Vindesine

First Posted Date: 2019-08-02

Last Posted Date: 2024-07-10

Lead Sponsor: University Hospital Muenster

Target Recruit Count: 683

Registration Number: NCT04043494

Locations: 🇳🇱
Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands
🇫🇷
Unité d'hématologie pédiatrique CHRU de Lille - Hôpital Jeanne de Flandre, Lille, France
🇧🇪
UZ Antwerpen Kinderhemato-oncologie, Edegem, Belgium

and more 219 locations

Biomarker Guided Treatment in DLBCL

Phase 2

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Rituximab
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Ibrutinib
Drug: Lenalidomide
Drug: chidamide
Drug: decitabine

First Posted Date: 2019-07-19

Last Posted Date: 2020-11-19

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 128

Registration Number: NCT04025593

Locations: 🇨🇳
Ruijin hospital, Shanghai, Shanghai, China

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Recurrent B Acute Lymphoblastic Leukemia
Refractory B Lymphoblastic Lymphoma
Recurrent B Lymphoblastic Lymphoma
Refractory B Acute Lymphoblastic Leukemia

Interventions: Drug: Etoposide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Cyclophosphamide
Biological: Inotuzumab Ozogamicin

First Posted Date: 2019-06-19

Last Posted Date: 2023-07-06

Lead Sponsor: University of Washington

Target Recruit Count: 24

Registration Number: NCT03991884

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Phase 2

Active, not recruiting

Conditions: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Diffuse Large B-Cell Lymphoma
Double-Expressor Lymphoma
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
High Grade B-Cell Lymphoma, Not Otherwise Specified
Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present
Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Procedure: Lumbar Puncture
Procedure: Positron Emission Tomography
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate
Drug: Venetoclax

First Posted Date: 2019-06-13

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 363

Registration Number: NCT03984448

Locations: 🇺🇸
Saint Anthony Hospital, Lakewood, Colorado, United States
🇺🇸
Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States
🇺🇸
Littleton Adventist Hospital, Littleton, Colorado, United States

and more 633 locations

Prednisone Reduction in ICU Patients With COPD Exacerbation

Phase 4

Conditions: Copd Exacerbation Acute
Mechanical Ventilation

Interventions: Drug: Prednisone

First Posted Date: 2019-06-10

Last Posted Date: 2019-06-10

Lead Sponsor: Hôpital Universitaire Fattouma Bourguiba

Target Recruit Count: 192

Registration Number: NCT03981081

Locations: 🇲🇦
CHU Ibn Cina, Rabat, Morocco
🇹🇳
CHU Tahar Sfar, Mahdia, Tunisia
🇲🇦
CHU Arrazi, Marrakech, Morocco

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy